Affinage

MKNK1

MAP kinase-interacting serine/threonine-protein kinase 1 · UniProt Q9BUB5

Length
465 aa
Mass
51.3 kDa
Annotated
2026-06-10
100 papers in source corpus 41 papers cited in narrative 41 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

MKNK1 (MNK1) is a serine/threonine kinase that integrates ERK1/2 and p38 MAPK signaling to control cap-dependent translation initiation and a set of additional substrate-specific outputs (PMID:9155017, PMID:9155018). Activated by direct phosphorylation from ERK and p38, MNK1 is recruited to the eIF4F complex through a direct interaction between its polybasic N-terminal region and the C-terminal HEAT-repeat (AA-box) domain of eIF4G, positioning it to phosphorylate eIF4E at Ser209 (PMID:9878069, PMID:12949082, PMID:16698552); genetic ablation of Mnk1/Mnk2 abolishes eIF4E Ser209 phosphorylation, establishing the MNKs as the exclusive eIF4E kinases, while bulk cap-dependent translation is unaffected (PMID:15254222). MNK1 acts on eIF4E independently of 4E-BP1 release and autoregulates its own dissociation from eIF4G after substrate phosphorylation, a step controlled by MAPK phosphorylation of its active site and restrained by its C-terminal domain (PMID:10022874, PMID:20823271). Beyond eIF4E, MNK1 phosphorylates cytosolic phospholipase A2 at Ser727 to drive arachidonate release (PMID:10978317), Sprouty2 at Ser112/Ser121 to stabilize it against ubiquitin-dependent degradation within an ERK feedback loop (PMID:16479008, PMID:27698061), and the synaptic RasGAP Syngap1 at Ser788 (PMID:36315645). Through these activities MNK1 governs activity- and growth-factor-dependent local translation in neurons (PMID:15447679, PMID:25609615, PMID:36315645), cytokinesis and abscission via centriolin/endobrevin localization to the midbody (PMID:22454512), immune effector responses (PMID:19574459, PMID:23269249), and metabolic and metastatic programs in tumor cells, where loss of MNK1 reduces glycolysis and selectively suppresses liver metastasis (PMID:20679220, PMID:30659022, PMID:39270021). MNK1 activity is negatively regulated by caspase-activated Pak2 phosphorylation at Thr22/Ser27, which blocks eIF4G binding, and its localization is controlled by a C-terminal CRM1-type nuclear export signal that maintains cytoplasmic residence (PMID:15234964, PMID:12949082). A genetic mouse study places the MNK1/Syngap1 axis in autism-related synaptic and memory phenotypes (PMID:36315645).

Mechanistic history

Synthesis pass · year-by-year structured walk · 17 steps
  1. 1997 High

    Established MNK1 as a MAPK-effector kinase by showing it is the convergence point of ERK and p38 signaling that phosphorylates eIF4E, answering what links mitogen/stress signaling to translation initiation.

    Evidence In vitro kinase assays, co-IP, dominant-negative/activated mutants, and pharmacological MEK/p38 inhibition; replicated in two simultaneous papers

    PMID:9155017 PMID:9155018

    Open questions at the time
    • Did not show eIF4E phosphorylation occurs on the endogenous eIF4F complex in cells
    • Physiological consequence of eIF4E Ser209 phosphorylation unaddressed
  2. 1999 High

    Defined the recruitment mechanism: MNK1 binds the eIF4G C-terminus to gain access to eIF4E and acts as the cellular eIF4E kinase independently of 4E-BP1, answering how a soluble kinase reaches its substrate.

    Evidence Co-IP/co-purification, eIF4E and MNK1 mutants, dominant-negative and activated MNK1 in cells

    PMID:10022874 PMID:9878069

    Open questions at the time
    • Structural basis of the eIF4G–MNK1 interaction not resolved at this stage
    • Regulation of binding by MAPK activity not yet established
  3. 2000 High

    Extended the substrate range beyond eIF4E by identifying cPLA2 Ser727 as a MNK1 site coupling the kinase to arachidonate/eicosanoid signaling.

    Evidence In vitro kinase assay with MS site mapping plus dominant-negative MNK1 and arachidonate release assay

    PMID:10978317

    Open questions at the time
    • Whether cPLA2 is phosphorylated by MNK1 under physiological stimuli in vivo not shown
    • Single-lab finding
  4. 2000 High

    Demonstrated that the eIF4G C-terminus is a competitive node by showing adenovirus 100K protein evicts MNK1 to shut off cellular cap-dependent translation, validating the binding site's functional importance.

    Evidence In vitro competition with purified proteins, Co-IP, and temperature-sensitive viral mutants

    PMID:10880459 PMID:15220445

    Open questions at the time
    • Generality of viral eIF4G hijacking beyond adenovirus not addressed here
  5. 2004 High

    Provided genetic proof that MNK1/2 are the sole eIF4E kinases yet dispensable for bulk translation, reframing eIF4E phosphorylation as a regulatory rather than essential step.

    Evidence Single and double Mnk knockout mice, bicistronic reporters, in vivo stimulation, MEF analysis

    PMID:15254222

    Open questions at the time
    • Which specific mRNAs require eIF4E phosphorylation left undefined
    • Functional distinction between inducible Mnk1 and basal Mnk2 mechanistically incomplete
  6. 2004 High

    Mapped the localization and recruitment determinants — an N-terminal polybasic eIF4G/importin-α site and a C-terminal CRM1 NES — explaining how MNK1 is kept cytoplasmic and recruited to eIF4G.

    Evidence Systematic mutagenesis, nuclear/cytoplasmic fractionation, Co-IP, importin-α binding

    PMID:12949082

    Open questions at the time
    • Conditions triggering nuclear import not defined
    • Single lab
  7. 2004 High

    Identified caspase-activated Pak2 phosphorylation at Thr22/Ser27 as a negative regulatory input that disrupts eIF4G binding, linking apoptosis to downregulation of MNK1-driven translation.

    Evidence In vitro kinase assay, phosphopeptide mapping/Edman sequencing, eIF4G peptide binding assays, apoptosis induction

    PMID:15234964

    Open questions at the time
    • In-cell stoichiometry and physiological impact on translation during apoptosis not quantified
  8. 2004 Medium

    Characterized regulatory complexity through splice variant Mnk1b and upstream physiological inputs (NMDA/ERK in neurons), showing MAPK-independent and tissue-specific routes to eIF4E phosphorylation.

    Evidence Cloning and kinase assay of Mnk1b, subcellular localization; hippocampal slice pharmacology and synaptoneurosome assays

    PMID:15350534 PMID:15447679

    Open questions at the time
    • Endogenous function of nuclear Mnk1b unknown
    • Neuronal substrate spectrum beyond eIF4E not defined here
  9. 2005 Medium

    Distinguished MNK1 from MNK2 regulation and demonstrated, via the Drosophila Lk6 ortholog, a conserved diet-dependent eIF4E-mediated growth role.

    Evidence Catalytic/C-terminal mutagenesis with kinase and ERK-binding assays; Drosophila genetic epistasis with eIF4E

    PMID:15649360 PMID:16162500

    Open questions at the time
    • Mammalian relevance of the growth phenotype not tested
    • Single-lab biochemistry
  10. 2006 High

    Defined Sprouty2 (Ser112/Ser121) as a MNK1 substrate whose stabilization modulates ERK feedback, establishing a non-translational arm of MNK1 signaling.

    Evidence In vitro kinase assay, Spry2 mutants, MNK1 inhibition, ubiquitination and ERK activation assays

    PMID:16479008

    Open questions at the time
    • In vivo significance not addressed until later cardiac work
  11. 2006 High

    Solved the eIF4G C-terminal HEAT-repeat structure and mapped the MNK1-binding AA-box motifs, providing the structural basis for kinase recruitment.

    Evidence X-ray crystallography (2.2 Å) with structure-guided surface mutagenesis and binding assays

    PMID:16698552

    Open questions at the time
    • No co-structure of the eIF4G–MNK1 complex
    • Conformational dynamics of recruitment not captured
  12. 2010 High

    Resolved the autoregulatory logic: MAPK phosphorylation of the MNK1 active site licenses eIF4G binding, and the kinase releases itself after phosphorylating eIF4E, explaining transient, signal-gated substrate access.

    Evidence Co-IP, splice variant analysis, kinase-dead mutant, and small-molecule inhibitor

    PMID:20823271

    Open questions at the time
    • Structural conformational changes underlying release not visualized
  13. 2012 High

    Uncovered a translation-independent role in cell division, showing MNK1 kinase activity is required for abscission via centriolin and endobrevin localization to the midbody.

    Evidence RNAi with rescue, kinase-dead mutant, chemical inhibitor, live imaging, immunofluorescence

    PMID:22454512

    Open questions at the time
    • Direct midbody substrate of MNK1 not identified
    • Mechanism linking kinase activity to centriolin localization unresolved
  14. 2013 Medium

    Established context-specific upstream activation, including a TAK1-p38 route in neutrophils controlling antiapoptotic Mcl-1 translation, broadening the inputs that engage MNK1.

    Evidence Multi-kinase pharmacological dissection, overexpression, cytokine protein vs mRNA, apoptosis assays

    PMID:23401599

    Open questions at the time
    • Genetic confirmation of TAK1-p38-MNK1 axis lacking
    • Direct vs indirect effects on S6K/4E-BP1 not separated
  15. 2017 Medium

    Identified specific oncogenic translational targets (SNAI1, CCNE1) downstream of C-KIT–MNK1/2–eIF4E, linking the kinase to melanoma cell migration and tumorigenicity.

    Evidence Genetic MNK1/2 depletion, selective MNK inhibitor SEL201, migration and tumor assays

    PMID:29035277

    Open questions at the time
    • Direct demonstration that these mRNAs are translationally regulated via eIF4E phosphorylation incomplete
    • Single lab
  16. 2023 High

    Demonstrated a phospho-eIF4E-independent function in cognition by identifying Syngap1 Ser788 as a MNK substrate whose dysregulation underlies memory deficits, reframing MNK signaling in neurodevelopmental disease.

    Evidence Mnk1/2 double KO, phospho-eIF4E knock-in, Syngap1 Co-IP, translational profiling, Syngap1 knockdown and pharmacological rescue, behavior

    PMID:36315645

    Open questions at the time
    • Direct in vitro phosphorylation of Syngap1 Ser788 by MNK1 not shown
    • Mechanism linking Syngap1 phosphorylation to plasticity incomplete
  17. 2024 High

    Connected MNK1 to tumor metabolic adaptation, showing its loss shifts cells from glycolysis to oxidative phosphorylation and selectively blocks liver metastasis, defining a metabolic output of the kinase.

    Evidence MNK1 KO cancer lines, multi-omics, glycolysis/OXPHOS assays, organ-specific in vivo metastasis

    PMID:39270021

    Open questions at the time
    • Substrate or translational target mediating the metabolic switch not identified
    • Basis of liver- vs lung-selective effect unresolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • The molecular events bridging MNK1 kinase activity to its many phospho-eIF4E-independent outputs (cytokinesis, metabolic reprogramming, organ-selective metastasis) remain to be defined at the level of direct substrates.
  • No direct midbody or metabolic substrate identified
  • No co-structure of MNK1 with eIF4G or any substrate
  • Division of labor between MNK1 and MNK2 across tissues incompletely mapped

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 5 GO:0016740 transferase activity 3 GO:0140110 transcription regulator activity 1
Localization
GO:0005634 nucleus 2 GO:0005829 cytosol 2 GO:0005815 microtubule organizing center 1 GO:0005856 cytoskeleton 1
Pathway
R-HSA-162582 Signal Transduction 4 R-HSA-392499 Metabolism of proteins 4 R-HSA-1643685 Disease 3 R-HSA-168256 Immune System 2 R-HSA-1430728 Metabolism 1 R-HSA-1640170 Cell Cycle 1 R-HSA-8953854 Metabolism of RNA 1
Partners
EIF4EEIF4G1HNRNPA1MAPK1MAPK14PAK2SPRY2SYNGAP1
Complex memberships
eIF4F translation initiation complex

Evidence

Reading pass · 41 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1997 MNK1 (Mnk1) binds tightly to ERK1/ERK2 and p38 MAP kinases; ERK and p38 phosphorylate and activate MNK1, which then phosphorylates eIF4E at Ser209 in vitro. MNK1 complexes more strongly with inactive than active Erk, suggesting dissociation after mitogen stimulation. Mitogen- and stress-mediated MNK1 activation is blocked by MEK1 and p38 inhibitors. In vitro kinase assays, co-immunoprecipitation, dominant-negative/activated mutant expression, pharmacological inhibition The EMBO journal High 9155017
1997 MNK1 is phosphorylated and activated in vitro by ERK1 and p38 MAP kinases but not by JNK/SAPK. Activation is differentially blocked by MEK inhibitor PD098059 or p38 inhibitor SB202190 in cells, placing MNK1 downstream of both ERK and p38 signaling branches. In vitro phosphorylation screening (solid-phase expression library), in vitro kinase assay, pharmacological inhibition in HeLa cells The EMBO journal High 9155018
1999 MNK1 is recruited to the eIF4F complex via direct interaction with the C-terminal region of eIF4G, enabling phosphorylation of eIF4E at Ser209. An eIF4E mutant lacking eIF4G-binding capability shows severely impaired phosphorylation in cells. MNK1 also interacts with the C-terminal region of p97 (an eIF4G-related protein), which may block eIF4E phosphorylation by sequestering MNK1. Co-immunoprecipitation, mutant eIF4E expression in cells, in vitro binding assays The EMBO journal High 9878069
1999 MNK1 binds directly to eIF4G and co-purifies with eIF4G and eIF4E in vivo. Dominant-negative MNK1 reduces mitogen-induced eIF4E phosphorylation; activated MNK1 increases basal eIF4E phosphorylation and can phosphorylate eIF4E even when 4EBP1 is overexpressed, establishing MNK1 as the cellular eIF4E kinase acting independently of 4EBP1 release. Co-purification, dominant-negative and activated mutant expression, in vivo phosphorylation assays Molecular and cellular biology High 10022874
2000 MNK1 phosphorylates cytosolic phospholipase A2 (cPLA2) in vitro uniquely on Ser-727 (identified by mass spectrometry). Expression of dominant-negative MNK1 in HEK293 cells significantly inhibits cPLA2-mediated arachidonate release, identifying cPLA2 as a physiological substrate of MNK1. In vitro kinase assay, mass spectrometry, dominant-negative MNK1 expression, arachidonate release assay The Journal of biological chemistry High 10978317
2000 Adenovirus inhibits cellular mRNA translation by displacing MNK1 from eIF4G via the viral 100K protein, which binds the C-terminus of eIF4G in vivo and in vitro at the same site as MNK1, thereby blocking eIF4E phosphorylation. Purified 100K protein evicts MNK1 from isolated eIF4F complexes in vitro. Co-immunoprecipitation, in vitro competition assays with purified proteins, temperature-sensitive viral mutant analysis The EMBO journal High 10880459
2004 Mnk1 and Mnk2 are the exclusive eIF4E kinases in fibroblasts and adult tissues. In Mnk1/Mnk2 double-knockout mice, eIF4E Ser209 is not phosphorylated even with ERK/p38 activation. Mnk1 is responsible for inducible eIF4E phosphorylation whereas Mnk2 mainly mediates constitutive/basal phosphorylation. Despite complete absence of phospho-eIF4E, general protein synthesis and cap-dependent translation are not affected. Genetic knockout (single and double KO mice), bicistronic reporter assay, LPS/insulin stimulation in vivo, embryonic fibroblast analysis Molecular and cellular biology High 15254222
2004 eIF4G recruits MNK1 through a structural interaction at its C-terminal HEAT-repeat domain; the eIF4G-binding site on MNK1 resides in a polybasic N-terminal region that also interacts with importin-α. MNK1 contains a CRM1-type nuclear export signal in its C-terminus; mutations abolishing export cause nuclear accumulation. Mutations reducing MNK1-eIF4G binding in vivo and in vitro also decrease eIF4E phosphorylation. Mutagenesis, nuclear/cytoplasmic fractionation, co-immunoprecipitation, importin-α binding assay The Journal of biological chemistry High 12949082
2004 The adenovirus 100K protein displaces MNK1 from eIF4G through a competitive binding mechanism; 100K protein and MNK1 share a common eIF4G-binding motif. Unlike MNK1, 100K binds eIF4G in an RNA-independent manner and with higher affinity, blocking cap-dependent cellular mRNA translation. Mutational analysis of 100K protein, in vitro competition binding assays, in vivo co-immunoprecipitation Journal of virology High 15220445
2004 HSV-1 ICP0 stimulates eIF4E phosphorylation (and 4E-BP1 phosphorylation) in infected cells in an MNK1-dependent manner; 4E-BP1 is degraded by the proteasome in an ICP0-dependent manner. Pharmacological inhibition of MNK1 dramatically reduces HSV-1 replication and viral polypeptide translation in quiescent cells. MNK1 inhibitor treatment, ICP0 mutant virus, proteasome inhibitor, viral protein synthesis and replication assays Genes & development Medium 15075293
2004 Caspase-activated Pak2/γ-PAK phosphorylates MNK1 at Thr22 and Ser27 (identified by tryptic phosphopeptide mapping and Edman degradation). This phosphorylation inhibits binding of eIF4G peptides to MNK1 by up to 80% and reduces MNK1-mediated phosphorylation of eIF4G (but not eIF4E) by up to 50%, suggesting a role for Pak2 in downregulating translation initiation during apoptosis. In vitro kinase assay, 2D tryptic phosphopeptide mapping, automated microsequencing, binding assays with eIF4G peptides, apoptosis induction in 293T cells The Journal of biological chemistry High 15234964
2004 MNK1 splice variant Mnk1b lacks the C-terminal ERK1/2 binding site and is therefore not phosphorylated/activated by ERK1/2, yet retains the ability to phosphorylate eIF4E in vitro and in vivo in a MAPK-independent manner. Mnk1b localizes to the nucleus (retaining NLS but lacking NES), whereas Mnk1 is exclusively cytoplasmic. Molecular cloning, in vitro kinase assay, immunofluorescence/subcellular fractionation, site-specific deletion analysis Experimental cell research Medium 15350534
2004 NMDA receptor activation in hippocampal CA1 results in PKA- and ERK-dependent activation of MNK1 and increased eIF4E phosphorylation. This signaling is present in synaptoneurosome preparations and occurs in dendrites, identifying a pathway coupling synaptic activity to local translation initiation. Hippocampal slice pharmacology (PKA, PKC, ERK inhibitors), MNK1 kinase activity assay, immunohistochemistry, synaptoneurosome fractionation Journal of neurochemistry Medium 15447679
2005 The Drosophila MNK1/2 homolog Lk6 regulates growth via eIF4E in a diet-dependent manner; overexpression of Lk6 causes growth inhibition in an eIF4E-dependent manner (genetic epistasis). Loss of Lk6 causes growth reduction under low-protein diet conditions. Drosophila genetics (loss-of-function, overexpression, epistasis with eIF4E mutants), body size measurements under dietary variation Current biology Medium 15649360
2005 Differences in basal activity and MAPK regulation between MNK1 and MNK2 are determined by features in both their catalytic domains and C-terminal MAPK-binding motifs. MNK2 (but not MNK1) can bind phosphorylated/active ERK, which protects ERK from dephosphorylation. An aspartate in MNK2's catalytic domain is essential for activity (Ala mutation inactivates MNK2). Association of MNKs with eIF4G is negatively modulated by MNK activity. Site-directed mutagenesis of catalytic domain and C-terminus, co-immunoprecipitation with ERK, kinase activity assays The Journal of biological chemistry Medium 16162500
2006 MNK1 phosphorylates human Sprouty2 (hSpry2) on Ser112 and Ser121. This phosphorylation stabilizes hSpry2 by antagonizing tyrosine phosphorylation, thereby reducing c-Cbl binding and polyubiquitination-dependent degradation. Loss of MNK1-mediated serine phosphorylation enhances hSpry2 degradation and impairs its inhibition of FGF-induced ERK activation. In vitro kinase assay, site-directed mutagenesis of Spry2, pharmacological MNK1 inhibition, ubiquitination assay, ERK activation assay Molecular and cellular biology High 16479008
2006 The X-ray crystal structure of the C-terminal HEAT-repeat domain of eIF4G (at 2.2 Å resolution) identifies two atypical HEAT domains; structure-guided mutagenesis maps the MNK1 binding site to two conserved aromatic/acidic-box (AA-box) motifs within the second HEAT domain. The acidic residues form a negatively charged surface interacting with basic residues in MNK1. X-ray crystallography (2.2 Å), structure-guided surface mutagenesis, protein-protein interaction assays Structure High 16698552
2007 MNK1 is a key downstream effector of MEKs in regulating HDM2 mRNA nuclear export; eIF4E promotes HDM2 mRNA export in a MEK- and MNK1-dependent manner through sequences in the 3' UTR of HDM2 mRNA. This pathway regulates mRNAs from both the P1 and P2 HDM2 promoters. Pharmacological MNK1 inhibition, eIF4E overexpression, mRNA export assay, 3'UTR reporter assay in breast cancer cells Oncogene Medium 17828301
2006 Inorganic phosphate (Pi) activates Mnk1 through an Akt-mediated MEK/ERK pathway and facilitates translocation of MNK1 from cytosol into nucleus, where it increases eIF4E-BP1 phosphorylation to stimulate cap-dependent protein translation. Subcellular fractionation, pharmacological pathway inhibition, phosphorylation assays in human bronchial epithelial cells American journal of respiratory cell and molecular biology Low 16763222
2008 Arsenic trioxide activates MNK1 and MNK2 phosphorylation in a p38α-dependent manner. In cells with targeted disruption of Mnk1/Mnk2 genes, arsenic-induced apoptosis is enhanced, establishing that MNK1/2 act as negative-feedback regulators of arsenic-induced apoptosis. Genetic knockout cells (Mnk1-/-, Mnk2-/-, double KO), pharmacological p38 inhibition, phosphorylation assays, apoptosis assays The Journal of biological chemistry High 18299328
2009 Type I IFNs induce phosphorylation/activation of MNK1, which requires upstream Jak1 and downstream MEK/ERK activation. MNK kinases are essential for mRNA translation of ISG15 and ISG54 genes in response to IFN. MNK kinase activity contributes to the growth inhibitory effects of type I IFNs on hematopoietic progenitors. Double Mnk1/Mnk2 KO MEFs, siRNA knockdown, pharmacological MNK inhibition, pathway inhibitors (Jak, MEK), mRNA translation assays PNAS High 19574459
2010 MAPK-mediated phosphorylation of the MNK1 active site controls eIF4G binding. The C-terminal domain of MNK1 restricts eIF4G interaction, preventing eIF4E phosphorylation in the absence of MAPK signaling. MNK1 autoregulates its interaction with eIF4G, releasing itself from the scaffold after phosphorylating eIF4E (demonstrated using a kinase-dead mutant and small-molecule inhibitor). Co-immunoprecipitation, naturally occurring splice variant analysis, small-molecule MNK1 inhibitor, kinase-dead MNK1 mutant Molecular and cellular biology High 20823271
2010 Loss of Mnk1/2 suppresses tumorigenesis in the Lck-Pten mouse lymphoma model; phospho-eIF4E is elevated in lymphomas of parental mice but absent in Mnk-DKO mice. Stable knockdown of MNK1 in U87MG glioma cells dramatically decreases tumor formation in athymic nude mice. Genetic double KO in cancer-prone mouse model, stable shRNA knockdown, xenograft tumor formation assay PNAS High 20679220
2011 PKCα phosphorylates eIF4G1 at Ser1186, which modulates eIF4G1 interaction with MNK1; PKCα activation triggers a cascade of eIF4G phosphorylation events that control binding of the eIF4E kinase MNK1 to the eIF4G scaffold. Phospho-proteomics, site-directed mutagenesis of eIF4G1, phorbol ester activation of PKCα, co-immunoprecipitation Molecular and cellular biology Medium 21576361
2011 MNK1 forms a complex with hnRNP A1 in vivo. Pharmacological inhibition of MNK1 decreases hnRNP A1 phosphorylation in young and senescent fibroblasts and blocks cytoplasmic accumulation of hnRNP A1 in senescent cells. MNK1 expression and phospho-MNK1 levels are elevated in senescent cells. Co-immunoprecipitation, pharmacological MNK1 inhibition (CGP57380), immunofluorescence, subcellular fractionation Experimental cell research Medium 22227431
2012 RSK phosphorylates MNK1, and this phosphorylation is required for MNK1 to mediate trastuzumab resistance in HER2+ breast cancer cells. MNK1 is transcriptionally regulated by YB-1 (confirmed by ChIP-PCR). MNK1 overexpression alone is sufficient to confer trastuzumab resistance in previously sensitive cells. ChIP-sequencing, ChIP-PCR, siRNA knockdown, overexpression, RSK inhibitor BI-D1870, kinase assay Oncogene Medium 22249268
2012 MNK1 kinase activity is required for cytokinesis/abscission; inhibition of MNK1 (chemical inhibitor, kinase-dead expression, or RNAi) induces multinucleated cells due to cytokinesis failure. Active MNK1 localizes to centrosomes, spindle microtubules, and the midbody. MNK1 depletion impairs centriolin localization at the midbody and consequently mislocalizes endobrevin (a v-SNARE), preventing membrane vesicle accumulation at the midbody. RNAi knockdown with rescue, kinase-dead mutant expression, chemical inhibitor, live-cell time-lapse imaging, immunofluorescence localization Journal of cell science High 22454512
2012 TCR engagement activates MNK1/2 in primary T cells in a Ras-ERK1/2-dependent manner, which is inhibited by diacylglycerol kinases α and ζ. Mnk1/2 double deficiency abolishes TCR-induced eIF4E Ser209 phosphorylation. Mnk1/2 deficiency causes decreased IL-17 and IFN-γ production by CD4 T cells after immunization, correlating with milder experimental autoimmune encephalomyelitis. Double KO mice, TCR stimulation, pharmacological pathway inhibitors, cytokine assays, EAE model Journal of immunology High 23269249
2013 MKNK1 facilitates hepatitis C virus (HCV) cell entry downstream of EGFR and ERK signaling; chemical inhibition or siRNA knockdown of MKNK1 significantly impairs entry of HCV genotype 1a and HCV-pseudotyped lentiviral particles with minimal impact on RNA replication. siRNA knockdown, chemical inhibitor panel, HCV pseudoparticle entry assay, replicon replication assay Journal of virology Medium 23365451
2013 MNK1 is activated downstream of TAK1-p38 MAPK in neutrophils (not MEK/ERK, JNK, PI3K, or PKC). MNK1 controls cytokine protein synthesis (but not mRNA levels) and mediates the antiapoptotic effect of LPS/TNF-α via Mcl-1 translation. MNK1 inhibition decreases phosphorylation of S6K, S6, and hyperphosphorylated 4E-BP1, and partially impairs late PI3K/Akt activation. Pharmacological inhibition of multiple kinases, MNK1 overexpression, cytokine protein vs. mRNA measurement, apoptosis assays, cap-binding assay Journal of leukocyte biology Medium 23401599
2014 MNK1 is a direct transcriptional target of the pancreatic transcription factor PTF1 (confirmed by ChIP). MNK1 is the principal eIF4E kinase in pancreatic acinar cells and is required for the physiological secretory response; Mnk1-/- acinar cells show defective enzyme relocalisation, polarity defects, and impaired secretory response in vitro and in vivo. Chromatin immunoprecipitation (ChIP), Mnk1 KO mice, secretin-stimulated MRI, in vitro amylase secretion assay, trypsinogen activation assay Gut High 25037190
2014 MNK1 pathway activity maintains protein synthesis in rapalog-treated gliomas; combined MNK1 knockdown and mTORC1 inhibition profoundly increases 4EBP1 binding to eIF4E, inhibits 4EBP1 phosphorylation at Ser65, reduces protein synthesis and proliferation, and reduces tumor growth in an orthotopic GBM mouse model. Cap analog (m7GTP) pulldown with quantitative mass spectrometry proteomics, MNK1 knockdown, pharmacological MNK/mTORC1 inhibition, orthotopic mouse model The Journal of clinical investigation High 24401275
2015 BDNF-induced upregulation of protein synthesis in cortical neurons requires MEK/ERK signaling and downstream MNK1, which phosphorylates eIF4E. MNK1 mediates BDNF-induced release of CYFIP1 (a translational repressor) from eIF4E. A subset of proteins involved in neurotransmission and synaptic plasticity has synthesis upregulated by BDNF via MNK1, with significant overlap with FMRP-bound mRNAs. Pharmacological and genetic approaches (Mnk1 KO), BONCAT+SILAC proteomics, co-immunoprecipitation (CYFIP1-eIF4E), protein synthesis measurement The Journal of neuroscience High 25609615
2016 MNK1-knockout mice are protected against high-fat diet-induced glucose intolerance and insulin resistance (but not obesity or adipose inflammation), demonstrating a distinct role for MNK1 in mediating HFD-induced insulin resistance. MNK1 and MNK2 single KO mouse models, high-fat diet feeding, glucose tolerance test, insulin sensitivity test, adipose tissue inflammation analysis Scientific reports Medium 27087055
2016 Mnk1 deficiency aggravates cardiac remodeling; Mnk1-KO mice show exaggerated hypertrophy, fibrosis, and dysfunction with increased ERK1/2 activation and reduced Sprouty2 expression. Overexpression of Sprouty2 rescues the exaggerated hypertrophic response in Mnk1-knockdown cardiomyocytes and in Mnk1-KO mice, placing MNK1 in the Sprouty2/ERK1/2 feedback pathway. Mnk1-KO mice with transverse aortic constriction, siRNA knockdown in NRVMs, adenoviral overexpression, Sprouty2 genetic rescue Hypertension High 27698061
2017 C-KIT stimulates MNK1/2, which phosphorylate eIF4E and render it oncogenic in acral/mucosal melanoma; MNK1/2 depletion inhibits cell migration and mRNA translation of SNAI1 and CCNE1, identifying these as translational targets that drive oncogenicity. MNK1/2 depletion (genetic), MNK inhibitor SEL201, polysome profiling (implied), cell migration and tumor formation assays The Journal of clinical investigation Medium 29035277
2018 Crystal structure-guided design of eFT508 (compound 23) reveals stereoelectronic interactions unique to MNK kinases; the inhibitor targets the ATP-binding site of MNK1/2 with exquisite selectivity. Crystal structure of MNK1 with inhibitor was used to guide medicinal chemistry. X-ray crystallography (structure-based drug design), kinase selectivity profiling, in vivo antitumor assays Journal of medicinal chemistry Medium 29526098
2019 MNK1 knockout in breast DCIS cells represses NODAL expression, inhibits DCIS-to-IDC conversion, and decreases metastasis; constitutively active MNK1 induces NODAL expression and promotes IDC. The MNK1/NODAL axis promotes cancer stem cell properties and invasion, identifying NODAL as a translational/transcriptional target downstream of MNK1. MNK1 KO and constitutively active MNK1 cell lines, orthotopic mammary injection, in vitro invasion and stem cell assays, MNK inhibitor SEL201 in vivo Cancer research High 30659022
2023 Mnk1/2 double knockout impairs synaptic plasticity and memory in mice independently of phospho-eIF4E (Ser209 ablation does not affect these processes). Syngap1 (a synaptic RasGAP encoded by an autism gene) co-immunoprecipitates with MNK1 and shows reduced phosphorylation at S788 in Mnk double-KO mice. Syngap1 knockdown reverses memory deficits in Mnk-DKO mice; pharmacological MNK inhibition rescues autism-related phenotypes in Syngap1+/- mice. Genetic double KO (Mnk1/2), phospho-eIF4E knock-in, co-immunoprecipitation (Syngap1-MNK1), translational profiling, Syngap1 knockdown rescue, behavioral assays Brain High 36315645
2021 FICD (FMS intracellular domain fragment generated by M-CSF receptor c-FMS proteolysis) forms a complex with DAP5; the FICD/DAP5 axis promotes osteoclast differentiation by activating MNK1/2 and EIF4E phosphorylation, enhancing NFATc1 protein expression. MNK1/2 pathway inhibition diminishes arthritic bone erosion. Co-immunoprecipitation (FICD-DAP5), myeloid-specific FICD transgenic mice, MNK1/2 pharmacological inhibition, inflammatory arthritis model, osteoclast differentiation assays Bone research Medium 34671034
2024 Loss of MNK1 restricts tumor cell metabolic adaptation by reducing glycolysis and increasing dependence on oxidative phosphorylation. MNK1-null breast and pancreatic tumor cells show suppressed metastasis specifically to the liver (but not the lung), identifying metabolic reprogramming as a consequence of MNK1 loss. MNK1 KO cancer cell lines, multi-omics (transcriptomics, proteomics, metabolomics), glycolysis/OXPHOS assays, in vivo metastasis models (liver vs. lung) Science advances High 39270021

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1997 Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. The EMBO journal 791 9155017
1997 MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. The EMBO journal 563 9155018
1999 Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. The EMBO journal 539 9878069
2004 Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Molecular and cellular biology 439 15254222
1999 Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo. Molecular and cellular biology 406 10022874
2000 Serine 727 phosphorylation and activation of cytosolic phospholipase A2 by MNK1-related protein kinases. The Journal of biological chemistry 202 10978317
2010 Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proceedings of the National Academy of Sciences of the United States of America 176 20679220
2004 Phosphorylation of eIF4E by Mnk-1 enhances HSV-1 translation and replication in quiescent cells. Genes & development 164 15075293
2018 Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition. Journal of medicinal chemistry 144 29526098
2010 Regulation of eukaryotic initiation factor 4E (eIF4E) phosphorylation by mitogen-activated protein kinase occurs through modulation of Mnk1-eIF4G interaction. Molecular and cellular biology 113 20823271
2018 Role of MAPK/MNK1 signaling in virus replication. Virus research 112 29864503
2000 Phosphorylation of the cap-binding protein eIF4E by the MAPK-activated protein kinase Mnk1. Biochemical pharmacology 91 11007962
2000 Adenovirus-specific translation by displacement of kinase Mnk1 from cap-initiation complex eIF4F. The EMBO journal 87 10880459
2004 NMDA receptor activation results in PKA- and ERK-dependent Mnk1 activation and increased eIF4E phosphorylation in hippocampal area CA1. Journal of neurochemistry 84 15447679
2006 Regulation of sprouty stability by Mnk1-dependent phosphorylation. Molecular and cellular biology 75 16479008
2014 MNK1 pathway activity maintains protein synthesis in rapalog-treated gliomas. The Journal of clinical investigation 67 24401275
2015 BDNF stimulation of protein synthesis in cortical neurons requires the MAP kinase-interacting kinase MNK1. The Journal of neuroscience : the official journal of the Society for Neuroscience 65 25609615
2009 Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses. Proceedings of the National Academy of Sciences of the United States of America 64 19574459
2020 Newcastle Disease virus infection activates PI3K/Akt/mTOR and p38 MAPK/Mnk1 pathways to benefit viral mRNA translation via interaction of the viral NP protein and host eIF4E. PLoS pathogens 63 32603377
2017 MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma. The Journal of clinical investigation 61 29035277
2005 Features of the catalytic domains and C termini of the MAPK signal-integrating kinases Mnk1 and Mnk2 determine their differing activities and regulatory properties. The Journal of biological chemistry 58 16162500
2017 Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors. Current medicinal chemistry 57 28164761
2011 Phosphorylation of eukaryotic translation initiation factor 4G1 (eIF4G1) by protein kinase C{alpha} regulates eIF4G1 binding to Mnk1. Molecular and cellular biology 56 21576361
2006 Elevated inorganic phosphate stimulates Akt-ERK1/2-Mnk1 signaling in human lung cells. American journal of respiratory cell and molecular biology 53 16763222
2021 Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses. The Journal of clinical investigation 52 33690225
2006 Two structurally atypical HEAT domains in the C-terminal portion of human eIF4G support binding to eIF4A and Mnk1. Structure (London, England : 1993) 52 16698552
2004 Identification and molecular characterization of Mnk1b, a splice variant of human MAP kinase-interacting kinase Mnk1. Experimental cell research 51 15350534
2006 MNK1 and MNK2 regulation in HER2-overexpressing breast cancer lines. The Journal of biological chemistry 48 17130135
2005 Diet-dependent effects of the Drosophila Mnk1/Mnk2 homolog Lk6 on growth via eIF4E. Current biology : CB 47 15649360
2017 Hyperactive mTOR and MNK1 phosphorylation of eIF4E confer tamoxifen resistance and estrogen independence through selective mRNA translation reprogramming. Genes & development 46 29269484
2012 MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition. Oncogene 46 22249268
2004 Structural basis for competitive inhibition of eIF4G-Mnk1 interaction by the adenovirus 100-kilodalton protein. Journal of virology 46 15220445
2021 The MNK1/2-eIF4E Axis Supports Immune Suppression and Metastasis in Postpartum Breast Cancer. Cancer research 41 33975880
2007 MNK1 and EIF4E are downstream effectors of MEKs in the regulation of the nuclear export of HDM2 mRNA. Oncogene 41 17828301
2003 Features in the N and C termini of the MAPK-interacting kinase Mnk1 mediate its nucleocytoplasmic shuttling. The Journal of biological chemistry 40 12949082
2018 Metformin blocks MYC protein synthesis in colorectal cancer via mTOR-4EBP-eIF4E and MNK1-eIF4G-eIF4E signaling. Molecular oncology 38 30221473
2015 Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia. PloS one 36 26317515
2017 Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation. Molecular cancer research : MCR 35 29042487
2016 MNK1 and MNK2 mediate adverse effects of high-fat feeding in distinct ways. Scientific reports 35 27087055
2004 Phosphorylation of Mnk1 by caspase-activated Pak2/gamma-PAK inhibits phosphorylation and interaction of eIF4G with Mnk. The Journal of biological chemistry 34 15234964
2019 MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ. Cancer research 31 30659022
2016 Mnk1 (Mitogen-Activated Protein Kinase-Interacting Kinase 1) Deficiency Aggravates Cardiac Remodeling in Mice. Hypertension (Dallas, Tex. : 1979) 29 27698061
2008 Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2. The Journal of biological chemistry 29 18299328
2004 Interleukins 2 and 15 regulate Ets1 expression via ERK1/2 and MNK1 in human natural killer cells. The Journal of biological chemistry 29 15563472
2020 The MNK1/2-eIF4E Axis as a Potential Therapeutic Target in Melanoma. International journal of molecular sciences 28 32517051
2013 BANK1 controls CpG-induced IL-6 secretion via a p38 and MNK1/2/eIF4E translation initiation pathway. Journal of immunology (Baltimore, Md. : 1950) 28 24227780
2018 MNK1 inhibitor as an antiviral agent suppresses buffalopox virus protein synthesis. Antiviral research 27 30393013
2013 Contrasting roles of mitogen-activated protein kinases in cellular entry and replication of hepatitis C virus: MKNK1 facilitates cell entry. Journal of virology 27 23365451
2004 The serine-threonine kinase MNK1 is post-translationally stabilized by PML-RARalpha and regulates differentiation of hematopoietic cells. Oncogene 27 15516979
2019 miR-483-5p Targets MKNK1 to Suppress Wilms' Tumor Cell Proliferation and Apoptosis In Vitro and In Vivo. Medical science monitor : international medical journal of experimental and clinical research 26 30798328
2019 The Novel Mnk1/2 Degrader and Apoptosis Inducer VNLG-152 Potently Inhibits TNBC Tumor Growth and Metastasis. Cancers 25 30832411
2013 Rational design of resorcylic acid lactone analogues as covalent MNK1/2 kinase inhibitors by tuning the reactivity of an enamide Michael acceptor. ChemMedChem 24 23929665
2012 Mnk1 and 2 are dispensable for T cell development and activation but important for the pathogenesis of experimental autoimmune encephalomyelitis. Journal of immunology (Baltimore, Md. : 1950) 24 23269249
2018 Design, synthesis and activity of Mnk1 and Mnk2 selective inhibitors containing thieno[2,3-d]pyrimidine scaffold. European journal of medicinal chemistry 23 30496989
2003 Mnk1 is required for angiotensin II-induced protein synthesis in vascular smooth muscle cells. Circulation research 23 14605021
2016 Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway. Biochemical and biophysical research communications 22 27520370
2013 Translational control of human neutrophil responses by MNK1. Journal of leukocyte biology 21 23401599
2018 MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells. Acta pharmacologica Sinica 20 30297804
2020 MNK1 signaling induces an ANGPTL4-mediated gene signature to drive melanoma progression. Oncogene 19 32132651
2023 A tRF-5a fragment that regulates radiation resistance of colorectal cancer cells by targeting MKNK1. Journal of cellular and molecular medicine 18 37864471
2021 miR-370-3p Regulates Adipogenesis through Targeting Mknk1. Molecules (Basel, Switzerland) 18 34834018
2013 TGFβ-induced PI 3 kinase-dependent Mnk-1 activation is necessary for Ser-209 phosphorylation of eIF4E and mesangial cell hypertrophy. Journal of cellular physiology 18 23359369
2021 MNK1 and MNK2 enforce expression of E2F1, FOXM1, and WEE1 to drive soft tissue sarcoma. Oncogene 17 33564073
2016 Discovery of a Selective and Potent Inhibitor of Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1/2) Utilizing Structure-Based Drug Design. Journal of medicinal chemistry 17 27002243
2004 Suppression of human Mnk1 by small interfering RNA increases the eukaryotic initiation factor 4F activity in HEK293T cells. FEBS letters 17 15581611
2019 Eukaryotic initiation factor 4E is a novel effector of mTORC1 signaling pathway in cross talk with Mnk1. Molecular and cellular biochemistry 15 31782083
2022 Novel AR/AR-V7 and Mnk1/2 Degrader, VNPP433-3β: Molecular Mechanisms of Action and Efficacy in AR-Overexpressing Castration Resistant Prostate Cancer In Vitro and In Vivo Models. Cells 14 36078112
2014 Mnk1 is a novel acinar cell-specific kinase required for exocrine pancreatic secretion and response to pancreatitis in mice. Gut 14 25037190
2011 MNK1 expression increases during cellular senescence and modulates the subcellular localization of hnRNP A1. Experimental cell research 14 22227431
2023 Mnk1/2 kinases regulate memory and autism-related behaviours via Syngap1. Brain : a journal of neurology 13 36315645
2017 Dysregulation of the MEK/ERK/MNK1 signalling cascade by middle T antigen of the trichoydsplasia spinulosa polyomavirus. Journal of the European Academy of Dermatology and Venereology : JEADV 13 28500640
2017 p38α regulates cytokine-induced IFNγ secretion via the Mnk1/eIF4E pathway in Th1 cells. Immunology and cell biology 13 28611474
2015 Identification of a Highly Conserved Allosteric Binding Site on Mnk1 and Mnk2. Molecular pharmacology 13 26268528
2019 Design, synthesis and biological evaluation of 4-aniline-thieno[2,3-d]pyrimidine derivatives as MNK1 inhibitors against renal cell carcinoma and nasopharyngeal carcinoma. Bioorganic & medicinal chemistry 12 31014565
2017 Small Molecules Targeting the Inactive Form of the Mnk1/2 Kinases. ACS omega 12 30023565
2015 Simplified molecular input line entry system-based: QSAR modelling for MAP kinase-interacting protein kinase (MNK1). SAR and QSAR in environmental research 12 25967103
2012 MNK1 kinase activity is required for abscission. Journal of cell science 12 22454512
2014 MNK1-induced eIF-4E phosphorylation in myeloma cells: a pathway mediating IL-6-induced expansion and expression of genes involved in metabolic and proteotoxic responses. PloS one 11 24714040
2023 Salinization Dramatically Enhance the Anti-Prostate Cancer Efficacies of AR/AR-V7 and Mnk1/2 Molecular Glue Degraders, Galeterone and VNPP433-3β Which Outperform Docetaxel and Enzalutamide in CRPC CWR22Rv1 Xenograft Mouse Model. Bioorganic chemistry 10 37392559
2022 Novel deuterated Mnk1/2 protein degrader VNLG-152R analogs: Synthesis, In vitro Anti-TNBC activities and pharmacokinetics in mice. European journal of medicinal chemistry 10 35617854
2021 Augmenting MNK1/2 activation by c-FMS proteolysis promotes osteoclastogenesis and arthritic bone erosion. Bone research 10 34671034
2015 PI4K-beta and MKNK1 are regulators of hepatitis C virus IRES-dependent translation. Scientific reports 10 26323588
2023 MNK1 and MNK2 Expression in the Human Dorsal Root and Trigeminal Ganglion. Neuroscience 9 36764601
2014 Possible role of p38 MAPK-MNK1-EMI2 cascade in metaphase-II arrest of mouse oocytes. Biology of reproduction 9 24920040
2023 Inhibition of the MNK1/2-eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer. Molecular cancer therapeutics 8 36722142
2022 Overcoming Paradoxical Kinase Priming by a Novel MNK1 Inhibitor. Journal of medicinal chemistry 8 35417652
2019 Design, synthesis and biological evaluation of pyridone-aminal derivatives as MNK1/2 inhibitors. Bioorganic & medicinal chemistry 8 30824167
2019 Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor. Biomolecules 8 31878201
2006 Regulation of c-jun mRNA expression in adult cardiocytes by MAP kinase interacting kinase-1 (MNK1). FASEB journal : official publication of the Federation of American Societies for Experimental Biology 8 16940435
2024 Development of an Imidazopyridazine-Based MNK1/2 Inhibitor for the Treatment of Lymphoma. Journal of medicinal chemistry 7 38564512
2021 Design, synthesis and biological evaluation of imidazopyridazine derivatives containing isoquinoline group as potent MNK1/2 inhibitors. Bioorganic & medicinal chemistry 6 33971490
2020 Discovery of indazole-pyridinone derivatives as a novel class of potent and selective MNK1/2 kinase inhibitors that protecting against endotoxin-induced septic shock. European journal of medicinal chemistry 6 33303237
2019 FLI1 promotes protein translation via the transcriptional regulation of MKNK1 expression. International journal of oncology 6 31894299
2025 Endocrine-exocrine miR-503-322 drives aging-associated pancreatitis via targeting MKNK1 in acinar cells. Nature communications 5 40097383
2024 Design, synthesis and biological evaluation of 4-(indolin-1-yl)-6-substituted-pyrido[3,2-d]pyrimidine derivatives as Mnk1/2 inhibitors. European journal of medicinal chemistry 5 38759457
2023 Identification of MKNK1 and TOP3A as ovarian endometriosis risk-associated genes using integrative genomic analyses and functional experiments. Computational and structural biotechnology journal 4 36851918
2023 An Aptamer against MNK1 for Non-Small Cell Lung Cancer Treatment. Pharmaceutics 4 37111758
2022 Proteomic characterization of spinal cord synaptoneurosomes from Tg-SOD1/G93A mice supports a role for MNK1 and local translation in the early stages of amyotrophic lateral sclerosis. Molecular and cellular neurosciences 4 36372157
2024 The role of MNK1-mTORC1 pathway in modulating macrophage responses to Vibrio vulnificus infection. Microbiology spectrum 3 38980024
2024 Blocking tumor-intrinsic MNK1 kinase restricts metabolic adaptation and diminishes liver metastasis. Science advances 3 39270021

Missed literature

Know a paper Affinage missed for MKNK1? Flag it for the maintainers and the community.

No submissions yet.